



Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: M.S. Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 18, 2005.

Kurt A. Summe
Kurt A. Summe, Reg. No. 36,023

4/18/05
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 10/681,431 **Filed:** October 8, 2003
Applicant: Moore et al.
Title: N-Desmethyl Levomepromazine
Art Unit: 1714 **Conf. No.:** 7143
Examiner: Shanham J. Sharareh
Atty Dkt: XANO-33

Cincinnati, Ohio 45202

April 18, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.704, the references listed on the attached supplemental Form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. Copies of the cited references are attached hereto.

The Examiner is respectfully requested to review each reference cited and to note the review on the attached PTO-1449 form and to reach their own independent determination of its materiality, if any.

A copy of the Search Report in counterpart International Application No. PCT/US2004/032956 is enclosed. This International Search Report was received in our

office on March 17, 2005. No fee is due for this submission in accordance with C.F.R. 37, §§ 1.97(e)(2) and 1.704(d).

Certification under 37 C.F.R. § 1.97(e)(2)

Each item of information contained in the Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Certification under 37 C.F.R. § 1.704(d)

The foreign patent office communication cited herein was not received by any individual designated in 1.56(c) more than thirty days prior to submission of this Supplemental Information Disclosure Statement.

Applicant knows of no fees due with this submission as this paper is filed on April 18, 2005, the first business day after the 30-day due date of April 17, 2005. However, should any fees be deemed required, the Commissioner is hereby authorized to charge any such fees to Deposit Account No. 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By 
Kurt A. Summe
Reg. No. 36,023

2700 Carew Tower
Cincinnati, OH 45202
(513) 241-2324
(513) 421-7269 (facsimile)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO. XANO/33		SERIAL NO. 10/681,431			
								APPLICANT Moore et al.					
								FILING DATE October 8, 2003		GROUP 1714			
(37 CFR 1.98(b))		(Use several sheets if necessary)						U.S. PATENT DOCUMENTS					

EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A	2	5	1	9	8	8	6	08/22/1950	Charpentier et al.				
	A.B	2	8	3	7	5	1	8	06/03/1958	Jacob et al.				
	A.C	8	5	1	9	5	1		10/19/1960	Smith Kline & French Labs.				
	A.D													
	A.E													
	A.F													
	A.G													
	A.H													
	A.I													
	A.J													
	A.K													

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	A.R	Dahl et al., <u>Binding Affinity of Levomepromazine and Two of its Major Metabolites to Central Dopamine and alpha-Adrenergic Receptors in the Rat</u> , PHARMACOLOGY, Vol. 74, 1981, pp. 101-104, XP009044395
	A.S	Hals et al., <u>Muscarinic Cholinergic and Histamine H1 Receptor Binding of Phenothiazine Drug Metabolites</u> , LIFE SCIENCES Vol. 43, No. 5, 1988, pp. 405-412, XP002318791
	A.T	Hals et al. , <u>Phenothiazine Drug Metabolites: Dopamine D2 Receptor, Alpha-1 and Alpha-2 Adrenoreceptor Binding</u> , EUROPEAN JOURNAL OF PHARMACOLOGY, Vol. 125, 1986 pp. 373-381, XP009044426

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. XANO/33		SERIAL NO. 10/681,431	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))			APPLICANT Keith Moore						
			FILING DATE October 8, 2003		GROUP 1714				
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		PATENT NUMBER		ISSUE DATE	PATENTEE		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A								
	B.B								
	B.C								
	B.D								
	B.E								
	B.F								
	B.G								
	B.H								
	B.I								
	B.J								
	B.K								
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS									
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE		CLASS	SUBCLASS	TRANSLATION (YES/NO)	
	B.L								
	B.M								
	B.N								
	B.O								
	B.P								
	B.Q								
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)									
	B.R	International Search Report for PCT/US2004/O32956, <u>mailed March 10, 2005</u>							
	B.S								
	B.T								
EXAMINER				DATE CONSIDERED					
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.									